One of the major investment themes at present is the ageing populations of developed economies. This offers an opportunity for healthcare companies such as CSL Limited (ASX: CSL), Ramsay Healthcare Limited (ASX: RHC) and Cochlear Limited (ASX: COH).

That’s because in the last five years the ageing population of the developed world has contributed to a mid-to-high-single digit annualised increase in healthcare industry revenue growth. In CSL’s case, I believe there is additional growth ahead.

Catalysts

By 2050, the number of people aged 60 or older will exceed the number of children for the first time in history. This means that demand for healthcare is likely to rise at a faster pace in the future. CSL is well-placed to take advantage of this through its geographical diversification across the major developed economies.

The approval of CSL830 could also benefit CSL over the medium term. This is a low volume subcutaneous and prophylactic version of its Berinert product. It is used to treat a rare condition called hereditary angioedema which causes painful swelling. It could be launched as soon as next year and I believe it has the potential to boost CSL’s earnings.

CSL’s influenza vaccine division will benefit from CSL’s track record of optimisation programmes. It is on track to record sales of US$1 billion by 2020. Further, influenza vaccines offer a relatively consistent growth outlook. Each year, between 5% and 10% of the world’s population contracts influenza. Forecast world population growth from 7.2 billion today to 9.7 billion in 2050 means that demand for influenza vaccines is likely to increase and provide CSL with growth opportunities.

Competitive Advantage

CSL has become increasingly cost competitive. It has developed manufacturing scale and its wide product range derived from plasma reduces its unit production cost. Further, CSL’s vertically integrated operating model provides a barrier to entry which lowers its overall risk profile in my opinion.

Strong cash flow provides scope for rising investment in CSL’s R&D. Although it spends a relatively low 7%-8% of revenue on product development each year, free cash flow of US$683 million last year means that this amount could be increased over the medium term. Additional borrowing could be accommodated on its balance sheet in order to fund further acquisitions. Or debt could be used to develop more collection centres to improve CSL’s competitive advantage versus its sector peers.

Outlook

Due to a favourable demographic tailwind, CSL has a bright long term future. Its innovation means that new product launches could positively catalyse earnings. Seqirus offers growth as well as a relatively consistent earnings profile. Further investment in R&D is made possible by CSL’s financial standing and its competitive cost base means that sales growth should easily filter down to bottom line growth.

In my view, now is the right time to buy CSL. And it could help you to make 100x your money, just as this world-famous investor has done since the age of 50.

How 1 Man Made 100x His Money After 50

Few know, that as Warren Buffett blew out the candles on his 50th birthday cake, he had just 1% of his current fortune. Think about it: At an age when most give up hope, Buffett was just getting started on the remaining 99% of his fortune. Goes to show you that it's never too late for you to potentially get rich. Which is why we've gathered the strategies we learned from Buffett, distilled them down to 11 simple lessons, and put it in an exclusive report for you to claim. Just click here to learn more about this handy investing guide.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Robert Stephens has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.